Charles J. Ryan, MD, University of California, discusses the advantages of giving androgen receptor targeting earlier to advanced disease patients, and a review of the STAMPEDE results.
To view slides from Dr. Ryan’s androgen receptor presentation at the 18th Annual Future Directions in Urology Symposium, click here.
To view slides from Dr. Ryan’s STAMPEDE results presentation at the 18th Annual Future Directions in Urology Symposium, click here.
“Keywords: prostate cancer, androgen receptor, STAMPEDE
